GBT (Global Blood Therapeutics)

OverviewSuggest Edit

GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The Company develops its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in an ongoing Phase 2a study in patients with idiopathic pulmonary fibrosis.

TypePublic
Founded2012
HQSouth San Francisco, US
Websitegbt.com
Employee Ratings4.8

Latest Updates

Employees (est.) (Dec 2018)171(+17%)
Share Price (Nov 2019)$47.2

GBT (Global Blood Therapeutics) Office Locations

GBT (Global Blood Therapeutics) has an office in South San Francisco
South San Francisco, US (HQ)
171 Oyster Point Blvd #300South
Show all (1)

GBT (Global Blood Therapeutics) Financials and Metrics

GBT (Global Blood Therapeutics) Revenue

USD

Net income (FY, 2018)

(174.2m)

EBIT (FY, 2018)

(182.7m)

Market capitalization (7-Nov-2019)

2.8b

Closing stock price (7-Nov-2019)

47.2

Cash (31-Dec-2018)

275.4m
GBT (Global Blood Therapeutics)'s current market capitalization is $2.8 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

9.7m21.9m31.4m51.4m

R&D expense

36.7m61.2m87.8m131.3m

Operating expense total

46.4m83.1m119.2m182.7m

EBIT

(46.4m)(83.1m)(119.2m)(182.7m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

1.5m2.7m4.3m4.5m6.0m6.4m6.2m8.2m12.8m10.9m

R&D expense

7.1m12.1m12.4m13.3m15.1m17.3m18.3m21.0m29.9m31.6m

Operating expense total

8.6m14.8m16.7m17.8m21.1m23.7m24.4m29.2m42.7m42.5m

EBIT

(8.6m)(14.8m)(16.7m)(17.8m)(21.1m)(23.7m)(24.4m)(29.2m)(42.7m)(42.5m)
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

148.5m92.1m198.3m275.4m

Accounts Receivable

2.1m

Current Assets

150.8m149.8m324.3m485.8m

PP&E

2.1m2.4m16.6m15.0m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

158.5m134.0m231.9m217.8m135.7m93.7m84.1m455.6m342.1m

Current Assets

160.7m136.5m234.1m221.3m248.3m234.9m229.8m553.9m469.5m

PP&E

2.2m2.3m2.6m2.6m2.4m5.2m13.2m17.4m17.1m

Total Assets

163.0m139.0m236.8m224.0m317.7m301.9m284.1m573.4m539.2m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(82.5m)(117.0m)(174.2m)

Depreciation and Amortization

1.2m1.7m4.6m

Accounts Payable

1.1m2.8m(1.3m)

Cash From Operating Activities

(67.7m)(93.0m)(135.4m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(8.6m)(14.8m)(16.6m)(34.3m)(21.0m)(23.3m)(75.8m)(41.6m)(81.9m)

Depreciation and Amortization

520.0k1.0m670.0k1.3m

Accounts Payable

1.5m1.4m4.3m1.2m3.0m3.1m(939.0k)262.0k(3.7m)

Cash From Operating Activities

(28.9m)(67.7m)(36.8m)(70.9m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

GBT (Global Blood Therapeutics) Online and Social Media Presence

Embed Graph

GBT (Global Blood Therapeutics) News and Updates

Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug

Shares of Global Blood Therapeutics Inc. shot up 40% Monday morning after the biotech company announced it had reached an agreement with the U.S. Food and Drug Administration to use an accelerated approval pathway for a potential sickle cell disease treatment. Voxelator, a once-a-day oral drug, wor…

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per share. If you are an ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529,...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT)

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are encouraged to obtain...
Show more

GBT (Global Blood Therapeutics) Blogs

GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor

First of Several Post -hoc Analyses Planned Using HOPE Study Clinical Data Findings Presented in Poster Session at 13 th Annual Academy for Sickle Cell and Thalassemia Conference SOUTH SAN FRANCISCO, Calif. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.

GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention

SOUTH SAN FRANCISCO, Calif. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts related to its sickle cell disease (SCD) research have been accepted for oral and poster presentations during the 47 th Annual National Sickle Cell

GBT to Host Analyst & Investor Day on October 8 in New York

SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. , (GBT) (NASDAQ: GBT) today announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy for voxelotor fo…

GBT Announces Participation at the 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019 , at 10:05 a.m. Eastern Time .

GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second quarter ended June 30, 2019 . “We accomplished several significant milestones in the second quarter of

GBT Announces Participation at the 2019 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 13, 2019 , at 1:55 p.m. Eastern Time .
Show more

GBT (Global Blood Therapeutics) Frequently Asked Questions

  • When was GBT (Global Blood Therapeutics) founded?

    GBT (Global Blood Therapeutics) was founded in 2012.

  • How many employees does GBT (Global Blood Therapeutics) have?

    GBT (Global Blood Therapeutics) has 171 employees.

  • Who are GBT (Global Blood Therapeutics) competitors?

    Competitors of GBT (Global Blood Therapeutics) include Cardiorentis, Retrophin and Albireo Pharma.

  • Where is GBT (Global Blood Therapeutics) headquarters?

    GBT (Global Blood Therapeutics) headquarters is located at 171 Oyster Point Blvd #300South, South San Francisco.

  • Where are GBT (Global Blood Therapeutics) offices?

    GBT (Global Blood Therapeutics) has an office in South San Francisco.

  • How many offices does GBT (Global Blood Therapeutics) have?

    GBT (Global Blood Therapeutics) has 1 office.